Scynexis (SCYX): Attractive Drug, Low Valuation, Consolidating Industry - Guggeheim

August 17, 2016 6:38 AM EDT
Get Alerts SCYX Hot Sheet
Price: $3.71 +0.27%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 7
Trade SCYX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Guggenheim analyst, Louise Chen, initiated coverage on shares of SCYNEXIS (NASDAQ: SCYX) with a Buy rating and a price target of $15.

The buy thesis has 3 points:

1) SCY-078 for IC (invasive candidiasis) has the potential to be best-in-class antifungal with the only IV to oral step down available for first line treatment of IC, if approved. Peak end market sales could be $1B+, by our estimates

2) SCY-078 for rVVC (recurrent vulvovaginal candidiasis, 4+ a year) has the potential to address an unmet need with greater efficacy than the standard of care. Peak end market sales could reach ~$500MM if the drug is approved. There could be spillover into acute VVC (women who get close to 4 yeast infections a year, or women with severe symptoms)

3) SCYX is an attractive company in a consolidating industry

SCYX’s Specialty Pharma peers trade at a forward EV/EBIT of 9.2x. Specialty Pharma companies have historically been acquired at EV/EBITDA multiples of 13.5x, which means the EV/EBIT multiple could be even higher. Although there is not a perfect comp for SCYX, other similar companies have market caps or have been acquired for a range of $163MM to $5,200MM leaving the company comfortably below the range with a market cap of only $48MM.

For an analyst ratings summary and ratings history on SCYNEXIS click here. For more ratings news on SCYNEXIS click here.

Shares of SCYNEXIS closed at $2.06 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Hot Comments, Hot New Coverage, New Coverage

Related Entities

Louise Chen, Guggenheim

Add Your Comment